Compare Regeneron Pharmaceuticals Inc (REGN) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Upwork Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Upwork Inc trades at $8.96 (market cap $1.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 62.1× Upwork Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| REGN | UPWK | |
|---|---|---|
Market Cap | $70.79B | $1.14B |
Sector | Health | Industrials |
52-Week High | $812.27 | $22.11 |
52-Week Low | $545.46 | $7.84 |
Enterprise Value | $64.74B | $934.87M |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
UPWK trades at $9.19, up 1.43% today, with a bullish technical signal from moving averages. The company reported $788M revenue in 2025 with strong profitability margins (net income margin 13.81%) and attractive valuation ratios (P/E 11.52, P/S 1.64). Recent news highlights AI integration initiatives and Q2 2026 earnings anticipation, though legal investigations pose sentiment headwinds.
The outlook is cautiously optimistic with a $10.67 analyst price target suggesting 16% upside. Key opportunities include sustained revenue growth and AI-powered marketplace expansion, while risks involve earnings misses, legal overhangs, and competitive pressures in the gig economy space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
